| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 254 | 2026 | 1541 | 24.040 |
Why?
|
| Genome-Wide Association Study | 259 | 2026 | 1840 | 18.370 |
Why?
|
| Genetic Predisposition to Disease | 325 | 2026 | 3410 | 15.390 |
Why?
|
| Polymorphism, Single Nucleotide | 318 | 2026 | 2846 | 14.780 |
Why?
|
| Smoking | 116 | 2026 | 930 | 8.050 |
Why?
|
| Models, Genetic | 88 | 2021 | 747 | 6.860 |
Why?
|
| Genetic Linkage | 90 | 2021 | 462 | 6.120 |
Why?
|
| Melanoma | 68 | 2025 | 917 | 6.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 37 | 2026 | 341 | 5.860 |
Why?
|
| Biomarkers, Tumor | 53 | 2026 | 1608 | 4.830 |
Why?
|
| Case-Control Studies | 206 | 2026 | 3408 | 4.480 |
Why?
|
| Skin Neoplasms | 51 | 2024 | 898 | 4.390 |
Why?
|
| Carcinoma, Squamous Cell | 38 | 2026 | 754 | 4.370 |
Why?
|
| Linkage Disequilibrium | 50 | 2025 | 317 | 4.130 |
Why?
|
| Humans | 848 | 2026 | 130403 | 3.950 |
Why?
|
| Neoplasms | 51 | 2026 | 2946 | 3.920 |
Why?
|
| Chromosomes, Human, Pair 15 | 26 | 2018 | 144 | 3.830 |
Why?
|
| Genotype | 155 | 2023 | 2607 | 3.810 |
Why?
|
| Quantitative Trait Loci | 46 | 2026 | 304 | 3.680 |
Why?
|
| Colorectal Neoplasms | 37 | 2026 | 624 | 3.500 |
Why?
|
| Chromosome Mapping | 65 | 2022 | 1053 | 3.410 |
Why?
|
| Genome, Human | 45 | 2021 | 1322 | 3.390 |
Why?
|
| Arthritis, Rheumatoid | 46 | 2022 | 283 | 3.370 |
Why?
|
| Genetic Variation | 66 | 2023 | 1557 | 3.360 |
Why?
|
| Genetic Markers | 61 | 2018 | 597 | 3.170 |
Why?
|
| Models, Statistical | 38 | 2020 | 482 | 3.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 29 | 2025 | 2015 | 2.970 |
Why?
|
| Multifactorial Inheritance | 18 | 2026 | 172 | 2.910 |
Why?
|
| Adenocarcinoma | 37 | 2024 | 987 | 2.820 |
Why?
|
| Male | 451 | 2026 | 64486 | 2.770 |
Why?
|
| Middle Aged | 317 | 2026 | 28395 | 2.740 |
Why?
|
| Female | 474 | 2026 | 70343 | 2.700 |
Why?
|
| Risk Factors | 213 | 2026 | 10981 | 2.690 |
Why?
|
| Quantitative Trait, Heritable | 27 | 2018 | 104 | 2.590 |
Why?
|
| Genetic Loci | 33 | 2024 | 356 | 2.570 |
Why?
|
| Genetics, Population | 20 | 2017 | 180 | 2.530 |
Why?
|
| Neoplasm Proteins | 20 | 2021 | 678 | 2.520 |
Why?
|
| Alleles | 94 | 2026 | 1672 | 2.520 |
Why?
|
| Computer Simulation | 49 | 2021 | 677 | 2.400 |
Why?
|
| Mendelian Randomization Analysis | 26 | 2025 | 98 | 2.370 |
Why?
|
| Receptors, Nicotinic | 24 | 2020 | 114 | 2.360 |
Why?
|
| Liver Neoplasms | 14 | 2025 | 1395 | 2.290 |
Why?
|
| Gene Frequency | 56 | 2022 | 738 | 2.220 |
Why?
|
| Aged | 223 | 2026 | 20899 | 2.190 |
Why?
|
| Gene-Environment Interaction | 17 | 2026 | 126 | 2.180 |
Why?
|
| Genomics | 15 | 2025 | 1619 | 2.150 |
Why?
|
| Mutation | 65 | 2026 | 6129 | 2.140 |
Why?
|
| Haplotypes | 59 | 2025 | 522 | 2.080 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2025 | 1005 | 2.070 |
Why?
|
| Gene Expression Profiling | 27 | 2025 | 1828 | 2.040 |
Why?
|
| Algorithms | 18 | 2020 | 1680 | 2.010 |
Why?
|
| Selection, Genetic | 8 | 2024 | 156 | 2.010 |
Why?
|
| Crohn Disease | 11 | 2025 | 291 | 2.000 |
Why?
|
| Germ-Line Mutation | 32 | 2023 | 372 | 1.990 |
Why?
|
| Software | 23 | 2019 | 737 | 1.940 |
Why?
|
| Chromosomes, Human, Pair 5 | 20 | 2019 | 108 | 1.910 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 23 | 2022 | 66 | 1.770 |
Why?
|
| Chromosomes, Human, Pair 6 | 15 | 2021 | 137 | 1.760 |
Why?
|
| Principal Component Analysis | 7 | 2017 | 153 | 1.740 |
Why?
|
| Breast Neoplasms | 38 | 2019 | 2617 | 1.730 |
Why?
|
| Psoriasis | 4 | 2025 | 48 | 1.720 |
Why?
|
| Adult | 221 | 2026 | 31125 | 1.690 |
Why?
|
| Prognosis | 68 | 2026 | 4901 | 1.670 |
Why?
|
| Mutation, Missense | 19 | 2025 | 931 | 1.650 |
Why?
|
| Glioma | 19 | 2023 | 523 | 1.630 |
Why?
|
| Genetic Testing | 26 | 2025 | 1086 | 1.600 |
Why?
|
| DNA Methylation | 18 | 2026 | 1094 | 1.580 |
Why?
|
| Penetrance | 8 | 2025 | 109 | 1.580 |
Why?
|
| Polymorphism, Genetic | 40 | 2022 | 775 | 1.540 |
Why?
|
| Body Mass Index | 19 | 2026 | 1682 | 1.530 |
Why?
|
| High-Throughput Nucleotide Sequencing | 12 | 2018 | 913 | 1.480 |
Why?
|
| Ovarian Neoplasms | 21 | 2023 | 455 | 1.480 |
Why?
|
| Venous Thromboembolism | 9 | 2025 | 191 | 1.450 |
Why?
|
| Genomic Imprinting | 8 | 2020 | 124 | 1.440 |
Why?
|
| Phenotype | 60 | 2025 | 4475 | 1.390 |
Why?
|
| Prostatic Neoplasms | 22 | 2023 | 1398 | 1.380 |
Why?
|
| Nerve Tissue Proteins | 24 | 2020 | 1089 | 1.350 |
Why?
|
| Epistasis, Genetic | 10 | 2016 | 97 | 1.330 |
Why?
|
| Genetic Association Studies | 28 | 2022 | 823 | 1.260 |
Why?
|
| Liver Cirrhosis, Biliary | 11 | 2021 | 90 | 1.260 |
Why?
|
| Obesity | 19 | 2026 | 2383 | 1.240 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 2025 | 225 | 1.200 |
Why?
|
| Pedigree | 55 | 2026 | 1683 | 1.190 |
Why?
|
| Risk | 37 | 2024 | 731 | 1.170 |
Why?
|
| Risk Assessment | 48 | 2026 | 3692 | 1.160 |
Why?
|
| Aged, 80 and over | 79 | 2024 | 6773 | 1.150 |
Why?
|
| Tobacco Use Disorder | 13 | 2022 | 89 | 1.150 |
Why?
|
| HLA Antigens | 15 | 2026 | 225 | 1.140 |
Why?
|
| Logistic Models | 33 | 2022 | 1807 | 1.110 |
Why?
|
| Smoking Cessation | 13 | 2024 | 191 | 1.100 |
Why?
|
| Small Cell Lung Carcinoma | 9 | 2019 | 32 | 1.090 |
Why?
|
| Tumor Suppressor Protein p53 | 18 | 2026 | 727 | 1.090 |
Why?
|
| DNA-Binding Proteins | 30 | 2023 | 1949 | 1.080 |
Why?
|
| Immunotherapy | 4 | 2022 | 752 | 1.080 |
Why?
|
| Uniparental Disomy | 7 | 2023 | 43 | 1.070 |
Why?
|
| Genes, Neoplasm | 3 | 2019 | 80 | 1.060 |
Why?
|
| Telomerase | 12 | 2019 | 152 | 1.060 |
Why?
|
| Odds Ratio | 50 | 2022 | 1224 | 1.050 |
Why?
|
| Lung | 23 | 2023 | 1568 | 1.050 |
Why?
|
| Membrane Proteins | 16 | 2024 | 1603 | 1.040 |
Why?
|
| DNA Repair | 26 | 2017 | 576 | 1.030 |
Why?
|
| Colonic Polyps | 5 | 2026 | 81 | 1.030 |
Why?
|
| Polyadenylation | 2 | 2025 | 47 | 1.020 |
Why?
|
| Neoplasm Metastasis | 5 | 2025 | 702 | 1.020 |
Why?
|
| Peutz-Jeghers Syndrome | 11 | 2013 | 28 | 1.020 |
Why?
|
| Disease | 6 | 2017 | 124 | 1.020 |
Why?
|
| HLA-C Antigens | 2 | 2025 | 11 | 1.010 |
Why?
|
| Myositis | 6 | 2025 | 106 | 0.990 |
Why?
|
| DNA Copy Number Variations | 9 | 2024 | 1031 | 0.990 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2025 | 325 | 0.980 |
Why?
|
| Genes, BRCA2 | 11 | 2014 | 48 | 0.970 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 19 | 0.960 |
Why?
|
| Papillomavirus Infections | 6 | 2024 | 384 | 0.960 |
Why?
|
| DNA Mutational Analysis | 15 | 2017 | 788 | 0.950 |
Why?
|
| Early Detection of Cancer | 11 | 2026 | 417 | 0.950 |
Why?
|
| Computational Biology | 16 | 2020 | 869 | 0.940 |
Why?
|
| Family | 16 | 2020 | 579 | 0.940 |
Why?
|
| Neoplasms, Second Primary | 8 | 2023 | 140 | 0.930 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2016 | 592 | 0.930 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2023 | 74 | 0.920 |
Why?
|
| Head and Neck Neoplasms | 11 | 2022 | 633 | 0.910 |
Why?
|
| Chromosomes, Human | 12 | 2017 | 120 | 0.910 |
Why?
|
| Cloud Computing | 1 | 2025 | 15 | 0.910 |
Why?
|
| Li-Fraumeni Syndrome | 10 | 2022 | 49 | 0.900 |
Why?
|
| Sequence Analysis, RNA | 4 | 2025 | 417 | 0.900 |
Why?
|
| Environmental Exposure | 5 | 2024 | 289 | 0.890 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 696 | 0.890 |
Why?
|
| BRCA2 Protein | 9 | 2017 | 56 | 0.870 |
Why?
|
| Codon, Nonsense | 3 | 2022 | 140 | 0.860 |
Why?
|
| Heterozygote | 27 | 2026 | 721 | 0.860 |
Why?
|
| Genes, p53 | 13 | 2017 | 208 | 0.860 |
Why?
|
| Genes, BRCA1 | 10 | 2014 | 59 | 0.860 |
Why?
|
| Research Design | 9 | 2024 | 716 | 0.860 |
Why?
|
| Lod Score | 29 | 2021 | 126 | 0.850 |
Why?
|
| RNA, Long Noncoding | 2 | 2025 | 220 | 0.850 |
Why?
|
| United Kingdom | 11 | 2025 | 254 | 0.840 |
Why?
|
| Bayes Theorem | 13 | 2024 | 308 | 0.830 |
Why?
|
| Gene Expression | 11 | 2021 | 1488 | 0.830 |
Why?
|
| Adaptor Proteins, Signal Transducing | 14 | 2022 | 619 | 0.830 |
Why?
|
| Scleroderma, Systemic | 4 | 2019 | 130 | 0.820 |
Why?
|
| Alopecia Areata | 5 | 2015 | 11 | 0.810 |
Why?
|
| Sequence Deletion | 6 | 2023 | 521 | 0.810 |
Why?
|
| Telomere | 12 | 2023 | 220 | 0.800 |
Why?
|
| Signal Transduction | 23 | 2021 | 4649 | 0.800 |
Why?
|
| Chromosomes, Human, Pair 12 | 9 | 2019 | 92 | 0.800 |
Why?
|
| Acyltransferases | 2 | 2024 | 62 | 0.800 |
Why?
|
| Pulmonary Surfactants | 1 | 2023 | 45 | 0.790 |
Why?
|
| Pancreatic Neoplasms | 12 | 2021 | 741 | 0.780 |
Why?
|
| CpG Islands | 10 | 2026 | 344 | 0.780 |
Why?
|
| Chromosome Inversion | 2 | 2014 | 72 | 0.780 |
Why?
|
| Population Health | 1 | 2023 | 35 | 0.770 |
Why?
|
| Likelihood Functions | 18 | 2017 | 117 | 0.770 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2025 | 906 | 0.770 |
Why?
|
| Regression Analysis | 20 | 2022 | 759 | 0.760 |
Why?
|
| Biological Evolution | 6 | 2015 | 227 | 0.760 |
Why?
|
| Carrier Proteins | 18 | 2017 | 1005 | 0.760 |
Why?
|
| Molecular Epidemiology | 11 | 2015 | 145 | 0.760 |
Why?
|
| Databases, Genetic | 13 | 2021 | 507 | 0.750 |
Why?
|
| Autoimmune Diseases | 10 | 2024 | 264 | 0.740 |
Why?
|
| X Chromosome | 3 | 2023 | 329 | 0.740 |
Why?
|
| Models, Theoretical | 6 | 2016 | 363 | 0.720 |
Why?
|
| Communicable Disease Control | 4 | 2023 | 140 | 0.720 |
Why?
|
| Data Interpretation, Statistical | 12 | 2020 | 227 | 0.710 |
Why?
|
| Mesothelioma | 4 | 2026 | 92 | 0.710 |
Why?
|
| Adenoma | 3 | 2018 | 145 | 0.700 |
Why?
|
| Sample Size | 9 | 2017 | 85 | 0.700 |
Why?
|
| Quarantine | 1 | 2021 | 17 | 0.700 |
Why?
|
| Transcriptome | 9 | 2025 | 1130 | 0.690 |
Why?
|
| Health Behavior | 5 | 2020 | 388 | 0.690 |
Why?
|
| Exons | 10 | 2025 | 763 | 0.690 |
Why?
|
| Brain Neoplasms | 12 | 2023 | 1350 | 0.680 |
Why?
|
| Chromosome Aberrations | 12 | 2023 | 575 | 0.680 |
Why?
|
| Nuclear Proteins | 17 | 2015 | 1215 | 0.670 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 204 | 0.660 |
Why?
|
| Social Isolation | 1 | 2020 | 43 | 0.660 |
Why?
|
| Pulmonary Embolism | 5 | 2024 | 190 | 0.650 |
Why?
|
| United States | 44 | 2025 | 11826 | 0.650 |
Why?
|
| Smokers | 4 | 2026 | 49 | 0.650 |
Why?
|
| Alcohol Drinking | 9 | 2024 | 346 | 0.640 |
Why?
|
| Symporters | 4 | 2020 | 78 | 0.640 |
Why?
|
| Papillomaviridae | 3 | 2019 | 178 | 0.640 |
Why?
|
| Survival Analysis | 20 | 2020 | 1501 | 0.640 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2020 | 17 | 0.640 |
Why?
|
| Veterans | 5 | 2024 | 1792 | 0.640 |
Why?
|
| Meta-Analysis as Topic | 13 | 2022 | 169 | 0.630 |
Why?
|
| Proportional Hazards Models | 29 | 2026 | 1413 | 0.630 |
Why?
|
| Ketones | 1 | 2020 | 26 | 0.630 |
Why?
|
| Cohort Studies | 33 | 2023 | 5084 | 0.630 |
Why?
|
| Sequence Analysis, DNA | 14 | 2024 | 1723 | 0.630 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2020 | 36 | 0.630 |
Why?
|
| Repressor Proteins | 5 | 2021 | 773 | 0.620 |
Why?
|
| Liver Cirrhosis | 8 | 2024 | 909 | 0.600 |
Why?
|
| DNA Mismatch Repair | 3 | 2022 | 44 | 0.600 |
Why?
|
| DNA | 9 | 2023 | 1411 | 0.600 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 890 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 808 | 0.580 |
Why?
|
| Multivariate Analysis | 22 | 2022 | 1380 | 0.580 |
Why?
|
| Adolescent | 76 | 2023 | 20731 | 0.580 |
Why?
|
| Proteins | 10 | 2018 | 1006 | 0.580 |
Why?
|
| Occupational Exposure | 4 | 2024 | 138 | 0.570 |
Why?
|
| Pandemics | 5 | 2023 | 1154 | 0.570 |
Why?
|
| Telomere Homeostasis | 6 | 2019 | 48 | 0.570 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 12 | 2021 | 1004 | 0.560 |
Why?
|
| Residence Characteristics | 1 | 2021 | 290 | 0.560 |
Why?
|
| Predictive Value of Tests | 18 | 2024 | 2298 | 0.560 |
Why?
|
| Age of Onset | 29 | 2017 | 599 | 0.550 |
Why?
|
| Thrombotic Microangiopathies | 3 | 2023 | 49 | 0.540 |
Why?
|
| Point Mutation | 4 | 2021 | 332 | 0.540 |
Why?
|
| Analysis of Variance | 19 | 2016 | 938 | 0.540 |
Why?
|
| Leukocytes | 6 | 2023 | 208 | 0.530 |
Why?
|
| Inflammation | 9 | 2024 | 1481 | 0.520 |
Why?
|
| Mosaicism | 5 | 2022 | 251 | 0.520 |
Why?
|
| Precision Medicine | 8 | 2024 | 381 | 0.520 |
Why?
|
| Nuclear Family | 12 | 2006 | 50 | 0.520 |
Why?
|
| Mental Health | 1 | 2020 | 369 | 0.520 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2017 | 7 | 0.520 |
Why?
|
| RNA Splicing | 4 | 2017 | 236 | 0.520 |
Why?
|
| Colonoscopy | 5 | 2026 | 239 | 0.520 |
Why?
|
| Sex Determination Analysis | 1 | 2017 | 15 | 0.520 |
Why?
|
| Prospective Studies | 23 | 2025 | 6447 | 0.520 |
Why?
|
| Young Adult | 41 | 2021 | 9974 | 0.510 |
Why?
|
| Sex Chromosomes | 1 | 2017 | 29 | 0.510 |
Why?
|
| DNA, Neoplasm | 13 | 2017 | 284 | 0.510 |
Why?
|
| MicroRNAs | 5 | 2025 | 896 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 1 | 8 | 2012 | 145 | 0.500 |
Why?
|
| Family Health | 17 | 2017 | 243 | 0.500 |
Why?
|
| Registries | 11 | 2026 | 1603 | 0.500 |
Why?
|
| Pleural Neoplasms | 3 | 2023 | 81 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 7 | 5 | 2019 | 77 | 0.490 |
Why?
|
| Incidence | 19 | 2024 | 3346 | 0.490 |
Why?
|
| Gene Regulatory Networks | 7 | 2018 | 384 | 0.490 |
Why?
|
| Homozygote | 12 | 2023 | 540 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 13 | 2023 | 1221 | 0.480 |
Why?
|
| Neoplasm Staging | 13 | 2025 | 1300 | 0.480 |
Why?
|
| Age Factors | 24 | 2021 | 2835 | 0.480 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2025 | 1077 | 0.480 |
Why?
|
| Metabolic Networks and Pathways | 6 | 2020 | 193 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2011 | 79 | 0.460 |
Why?
|
| Reproducibility of Results | 22 | 2025 | 2923 | 0.460 |
Why?
|
| Datasets as Topic | 7 | 2021 | 100 | 0.460 |
Why?
|
| DNA, Viral | 1 | 2017 | 452 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 614 | 0.450 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2015 | 23 | 0.450 |
Why?
|
| Europe | 13 | 2024 | 366 | 0.450 |
Why?
|
| ErbB Receptors | 6 | 2020 | 294 | 0.450 |
Why?
|
| Nicotine | 5 | 2022 | 117 | 0.450 |
Why?
|
| Tissue Banks | 2 | 2013 | 29 | 0.450 |
Why?
|
| Skin | 6 | 2016 | 540 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 2 | 6 | 2016 | 121 | 0.440 |
Why?
|
| Bias | 7 | 2013 | 143 | 0.440 |
Why?
|
| Transcription Factors | 15 | 2024 | 2437 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 168 | 0.430 |
Why?
|
| C-Reactive Protein | 5 | 2023 | 450 | 0.430 |
Why?
|
| Genetic Techniques | 5 | 2002 | 96 | 0.430 |
Why?
|
| Survival Rate | 14 | 2020 | 2134 | 0.420 |
Why?
|
| ROC Curve | 12 | 2025 | 610 | 0.410 |
Why?
|
| Tobacco Smoking | 4 | 2023 | 20 | 0.410 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 265 | 0.400 |
Why?
|
| Peptides, Cyclic | 5 | 2008 | 45 | 0.400 |
Why?
|
| Genetic Diseases, Inborn | 4 | 2010 | 470 | 0.400 |
Why?
|
| Gene Expression Regulation | 7 | 2022 | 2343 | 0.400 |
Why?
|
| Sex Factors | 13 | 2021 | 1333 | 0.400 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 9 | 2026 | 650 | 0.400 |
Why?
|
| Leukemia | 1 | 2016 | 373 | 0.400 |
Why?
|
| Texas | 23 | 2024 | 3614 | 0.400 |
Why?
|
| RNA, Messenger | 11 | 2025 | 2553 | 0.390 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 3702 | 0.390 |
Why?
|
| BRCA1 Protein | 6 | 2017 | 82 | 0.390 |
Why?
|
| Lung Diseases | 4 | 2026 | 401 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 22 | 2016 | 1454 | 0.390 |
Why?
|
| Life Style | 5 | 2025 | 446 | 0.390 |
Why?
|
| Cardiovascular Diseases | 11 | 2024 | 2098 | 0.380 |
Why?
|
| Comorbidity | 4 | 2026 | 1587 | 0.380 |
Why?
|
| Radon | 3 | 2024 | 11 | 0.380 |
Why?
|
| Linear Models | 8 | 2019 | 689 | 0.380 |
Why?
|
| Gene Pool | 1 | 2012 | 5 | 0.380 |
Why?
|
| Receptors, Estrogen | 4 | 2017 | 727 | 0.380 |
Why?
|
| Single-Cell Analysis | 4 | 2024 | 357 | 0.380 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 5 | 0.370 |
Why?
|
| Microsatellite Repeats | 16 | 2009 | 210 | 0.370 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2022 | 56 | 0.370 |
Why?
|
| HLA-DRB1 Chains | 9 | 2025 | 46 | 0.370 |
Why?
|
| Venous Thrombosis | 3 | 2024 | 172 | 0.360 |
Why?
|
| Gene Deletion | 4 | 2014 | 770 | 0.360 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2021 | 93 | 0.360 |
Why?
|
| Data Mining | 3 | 2025 | 65 | 0.360 |
Why?
|
| Telomere-Binding Proteins | 4 | 2017 | 45 | 0.350 |
Why?
|
| Research | 3 | 2022 | 264 | 0.350 |
Why?
|
| Receptors, Progesterone | 3 | 2014 | 675 | 0.350 |
Why?
|
| Glioblastoma | 3 | 2023 | 379 | 0.350 |
Why?
|
| Interferon Regulatory Factors | 4 | 2023 | 45 | 0.340 |
Why?
|
| Major Histocompatibility Complex | 6 | 2018 | 49 | 0.340 |
Why?
|
| Colonic Neoplasms | 7 | 2021 | 262 | 0.340 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 145 | 0.340 |
Why?
|
| Esophageal Neoplasms | 3 | 2024 | 392 | 0.340 |
Why?
|
| Condoms | 2 | 2008 | 47 | 0.330 |
Why?
|
| Frailty | 2 | 2024 | 140 | 0.330 |
Why?
|
| Medical History Taking | 5 | 2021 | 109 | 0.330 |
Why?
|
| Mutagens | 9 | 2010 | 47 | 0.330 |
Why?
|
| Multigene Family | 6 | 2017 | 290 | 0.330 |
Why?
|
| HLA-DP beta-Chains | 3 | 2017 | 10 | 0.330 |
Why?
|
| HapMap Project | 4 | 2022 | 13 | 0.320 |
Why?
|
| Lymphocytes | 14 | 2013 | 345 | 0.320 |
Why?
|
| Surveys and Questionnaires | 18 | 2025 | 4015 | 0.320 |
Why?
|
| Autoantibodies | 10 | 2017 | 439 | 0.320 |
Why?
|
| HLA-DR Antigens | 9 | 2008 | 64 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 7 | 2020 | 582 | 0.320 |
Why?
|
| Retrospective Studies | 29 | 2024 | 17633 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2006 | 87 | 0.310 |
Why?
|
| Nevus | 3 | 2017 | 34 | 0.310 |
Why?
|
| Diabetes Mellitus | 5 | 2022 | 890 | 0.310 |
Why?
|
| Specimen Handling | 4 | 2024 | 145 | 0.310 |
Why?
|
| Asbestos | 2 | 2024 | 11 | 0.310 |
Why?
|
| Alcoholism | 4 | 2005 | 244 | 0.310 |
Why?
|
| Genome | 7 | 2010 | 465 | 0.300 |
Why?
|
| Body Size | 2 | 2022 | 58 | 0.300 |
Why?
|
| Thrombosis | 2 | 2025 | 496 | 0.300 |
Why?
|
| Body Height | 4 | 2021 | 196 | 0.300 |
Why?
|
| Cigarette Smoking | 2 | 2021 | 95 | 0.300 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 274 | 0.300 |
Why?
|
| Databases, Nucleic Acid | 2 | 2008 | 72 | 0.300 |
Why?
|
| North America | 5 | 2024 | 257 | 0.300 |
Why?
|
| Canada | 13 | 2013 | 321 | 0.300 |
Why?
|
| Siblings | 8 | 2007 | 203 | 0.300 |
Why?
|
| Interleukin-12 Subunit p40 | 3 | 2015 | 14 | 0.290 |
Why?
|
| Probability | 12 | 2011 | 306 | 0.290 |
Why?
|
| Models, Biological | 3 | 2017 | 1387 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 1262 | 0.290 |
Why?
|
| Primary Prevention | 3 | 2019 | 177 | 0.290 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 5204 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2018 | 111 | 0.290 |
Why?
|
| Bleomycin | 12 | 2010 | 118 | 0.290 |
Why?
|
| Cytochrome P-450 CYP2A6 | 5 | 2026 | 12 | 0.290 |
Why?
|
| Hepatitis C | 2 | 2023 | 388 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 2 | 2010 | 38 | 0.280 |
Why?
|
| Cholangiocarcinoma | 2 | 2023 | 124 | 0.280 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2024 | 79 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 2 | 2023 | 128 | 0.280 |
Why?
|
| Reproductive Behavior | 1 | 2008 | 7 | 0.280 |
Why?
|
| Electronic Health Records | 2 | 2025 | 812 | 0.280 |
Why?
|
| Crack Cocaine | 1 | 2008 | 4 | 0.280 |
Why?
|
| Statistics as Topic | 7 | 2012 | 239 | 0.280 |
Why?
|
| Population Dynamics | 1 | 2008 | 29 | 0.280 |
Why?
|
| Sexual Behavior, Animal | 1 | 2008 | 54 | 0.280 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 92 | 0.280 |
Why?
|
| Rheumatoid Factor | 2 | 2008 | 8 | 0.270 |
Why?
|
| Coronary Disease | 8 | 1994 | 628 | 0.270 |
Why?
|
| Ecosystem | 1 | 2008 | 90 | 0.270 |
Why?
|
| Disease-Free Survival | 10 | 2019 | 900 | 0.260 |
Why?
|
| Colitis, Ulcerative | 4 | 2024 | 215 | 0.260 |
Why?
|
| Genetic Counseling | 7 | 2019 | 236 | 0.260 |
Why?
|
| Lectins, C-Type | 2 | 2021 | 69 | 0.260 |
Why?
|
| Carcinoma | 4 | 2008 | 284 | 0.260 |
Why?
|
| Intention | 1 | 2008 | 101 | 0.260 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2023 | 487 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2012 | 54 | 0.260 |
Why?
|
| Polymyositis | 3 | 2023 | 17 | 0.250 |
Why?
|
| False Positive Reactions | 6 | 2016 | 143 | 0.250 |
Why?
|
| Genetic Pleiotropy | 2 | 2016 | 25 | 0.250 |
Why?
|
| Aging | 5 | 2016 | 1251 | 0.250 |
Why?
|
| Pigmentation | 4 | 2020 | 35 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 1311 | 0.250 |
Why?
|
| Natural Language Processing | 2 | 2025 | 77 | 0.250 |
Why?
|
| Circadian Rhythm | 2 | 2021 | 315 | 0.250 |
Why?
|
| Machine Learning | 3 | 2026 | 385 | 0.250 |
Why?
|
| Protein Tyrosine Phosphatases | 5 | 2007 | 76 | 0.240 |
Why?
|
| Community Health Services | 2 | 2019 | 87 | 0.240 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3805 | 0.240 |
Why?
|
| Endometrial Neoplasms | 2 | 2022 | 111 | 0.240 |
Why?
|
| Antigens, CD | 4 | 2018 | 412 | 0.240 |
Why?
|
| Sensitivity and Specificity | 9 | 2019 | 2111 | 0.240 |
Why?
|
| Genes | 4 | 2015 | 308 | 0.240 |
Why?
|
| Lipase | 2 | 2024 | 88 | 0.240 |
Why?
|
| Sexual Behavior | 1 | 2008 | 238 | 0.240 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 205 | 0.230 |
Why?
|
| Membrane Glycoproteins | 3 | 2015 | 411 | 0.230 |
Why?
|
| Thoracic Neoplasms | 1 | 2026 | 37 | 0.230 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 129 | 0.230 |
Why?
|
| Carcinogenesis | 5 | 2024 | 345 | 0.230 |
Why?
|
| Overweight | 2 | 2026 | 379 | 0.230 |
Why?
|
| Thymus Neoplasms | 1 | 2026 | 40 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2011 | 488 | 0.230 |
Why?
|
| Autoantigens | 3 | 2021 | 99 | 0.230 |
Why?
|
| Biometry | 4 | 2012 | 102 | 0.230 |
Why?
|
| Monte Carlo Method | 6 | 2010 | 100 | 0.230 |
Why?
|
| Nerve Fibers | 2 | 2022 | 69 | 0.230 |
Why?
|
| Stress, Psychological | 2 | 2025 | 544 | 0.230 |
Why?
|
| Occupational Diseases | 2 | 2018 | 77 | 0.230 |
Why?
|
| Granulomatosis with Polyangiitis | 2 | 2017 | 39 | 0.230 |
Why?
|
| Carcinogens | 8 | 2024 | 128 | 0.230 |
Why?
|
| Body Temperature Regulation | 1 | 2025 | 52 | 0.220 |
Why?
|
| Spondylitis, Ankylosing | 4 | 1998 | 14 | 0.220 |
Why?
|
| Aspartic Acid | 1 | 2025 | 78 | 0.220 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 6 | 2017 | 7 | 0.220 |
Why?
|
| Postprandial Period | 1 | 2025 | 87 | 0.220 |
Why?
|
| Information Storage and Retrieval | 1 | 2025 | 64 | 0.220 |
Why?
|
| Body Temperature | 1 | 2025 | 126 | 0.220 |
Why?
|
| Retinoid X Receptor alpha | 2 | 2016 | 16 | 0.220 |
Why?
|
| Air Pollution | 2 | 2024 | 76 | 0.210 |
Why?
|
| Child | 37 | 2024 | 26159 | 0.210 |
Why?
|
| Base Sequence | 15 | 2024 | 2753 | 0.210 |
Why?
|
| International Agencies | 2 | 2021 | 28 | 0.210 |
Why?
|
| Cell Cycle Proteins | 5 | 2016 | 704 | 0.210 |
Why?
|
| Macrophages | 3 | 2024 | 652 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 87 | 0.210 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2015 | 51 | 0.210 |
Why?
|
| Adipocytes | 1 | 2025 | 176 | 0.210 |
Why?
|
| Neoplasm Grading | 7 | 2019 | 279 | 0.210 |
Why?
|
| HLA-DQ beta-Chains | 3 | 2020 | 14 | 0.210 |
Why?
|
| Digestive System Neoplasms | 2 | 2021 | 11 | 0.210 |
Why?
|
| Cysteine Endopeptidases | 3 | 2013 | 110 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2026 | 239 | 0.210 |
Why?
|
| Rad52 DNA Repair and Recombination Protein | 2 | 2015 | 5 | 0.210 |
Why?
|
| Prevalence | 9 | 2024 | 2683 | 0.210 |
Why?
|
| Cathepsin H | 1 | 2023 | 1 | 0.200 |
Why?
|
| Introns | 2 | 2015 | 281 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2015 | 359 | 0.200 |
Why?
|
| Rare Diseases | 1 | 2026 | 208 | 0.200 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2003 | 14 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 494 | 0.200 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 30 | 0.200 |
Why?
|
| MutL Protein Homolog 1 | 8 | 2022 | 52 | 0.200 |
Why?
|
| Air Pollution, Indoor | 1 | 2024 | 82 | 0.200 |
Why?
|
| Tobacco Products | 1 | 2024 | 60 | 0.200 |
Why?
|
| Oncogenes | 3 | 2022 | 163 | 0.200 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2023 | 19 | 0.200 |
Why?
|
| Statistics, Nonparametric | 6 | 2015 | 427 | 0.200 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 129 | 0.200 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2023 | 30 | 0.200 |
Why?
|
| Vitamin D | 2 | 2016 | 198 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2020 | 392 | 0.200 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2018 | 60 | 0.200 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 2 | 2022 | 8 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 2015 | 364 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2024 | 187 | 0.190 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 126 | 0.190 |
Why?
|
| Quality Control | 3 | 2023 | 115 | 0.190 |
Why?
|
| Nucleic Acids | 1 | 2023 | 26 | 0.190 |
Why?
|
| Self Care | 1 | 2024 | 226 | 0.190 |
Why?
|
| Trans-Activators | 5 | 2016 | 689 | 0.190 |
Why?
|
| Phospholipases | 1 | 2022 | 9 | 0.190 |
Why?
|
| Medical Records | 2 | 2011 | 177 | 0.190 |
Why?
|
| Jews | 7 | 2020 | 34 | 0.190 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 1701 | 0.190 |
Why?
|
| Least-Squares Analysis | 3 | 2007 | 28 | 0.190 |
Why?
|
| Genes, Dominant | 10 | 2020 | 245 | 0.190 |
Why?
|
| Paraffin Embedding | 3 | 2023 | 42 | 0.190 |
Why?
|
| Anticoagulants | 3 | 2022 | 599 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 79 | 0.180 |
Why?
|
| Organ Specificity | 3 | 2019 | 396 | 0.180 |
Why?
|
| Phylogeny | 2 | 2017 | 705 | 0.180 |
Why?
|
| Macula Lutea | 1 | 2022 | 26 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 154 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 259 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2023 | 61 | 0.180 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2022 | 13 | 0.180 |
Why?
|
| RNA-Binding Proteins | 3 | 2022 | 541 | 0.180 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 109 | 0.180 |
Why?
|
| Isochromosomes | 1 | 2022 | 17 | 0.180 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2022 | 28 | 0.180 |
Why?
|
| Mutation Rate | 2 | 2019 | 68 | 0.180 |
Why?
|
| Malnutrition | 1 | 2024 | 155 | 0.180 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2023 | 66 | 0.180 |
Why?
|
| Animals | 28 | 2025 | 33852 | 0.180 |
Why?
|
| Astrocytoma | 1 | 2023 | 107 | 0.180 |
Why?
|
| Workplace | 1 | 2023 | 81 | 0.180 |
Why?
|
| Genes, MHC Class II | 3 | 2009 | 11 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2017 | 317 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2022 | 66 | 0.180 |
Why?
|
| DNA Adducts | 5 | 2010 | 70 | 0.180 |
Why?
|
| RNA, Neoplasm | 1 | 2022 | 126 | 0.180 |
Why?
|
| Guanylate Kinases | 1 | 2021 | 18 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 499 | 0.180 |
Why?
|
| Recombination, Genetic | 7 | 2007 | 422 | 0.170 |
Why?
|
| Retina | 2 | 2022 | 452 | 0.170 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2017 | 154 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 262 | 0.170 |
Why?
|
| Genotyping Techniques | 6 | 2020 | 111 | 0.170 |
Why?
|
| Germ Cells | 4 | 2023 | 200 | 0.170 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2001 | 8 | 0.170 |
Why?
|
| Membrane Transport Proteins | 4 | 2013 | 179 | 0.170 |
Why?
|
| Frontotemporal Dementia | 1 | 2022 | 65 | 0.170 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 65 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 604 | 0.170 |
Why?
|
| HLA-B27 Antigen | 3 | 1997 | 5 | 0.170 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 73 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 26 | 0.170 |
Why?
|
| Parkinson Disease | 2 | 2023 | 722 | 0.170 |
Why?
|
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2021 | 23 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2020 | 98 | 0.170 |
Why?
|
| Human papillomavirus 16 | 1 | 2021 | 97 | 0.170 |
Why?
|
| Apoptosis | 6 | 2011 | 1840 | 0.170 |
Why?
|
| Proprotein Convertase 9 | 1 | 2021 | 110 | 0.170 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 2 | 2026 | 14 | 0.170 |
Why?
|
| Periodontal Diseases | 1 | 2021 | 31 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 4 | 6 | 2019 | 53 | 0.170 |
Why?
|
| Loss of Function Mutation | 2 | 2019 | 170 | 0.170 |
Why?
|
| Spatial Analysis | 1 | 2021 | 27 | 0.170 |
Why?
|
| Dendritic Cells | 2 | 2021 | 435 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1487 | 0.170 |
Why?
|
| Education | 1 | 2021 | 111 | 0.170 |
Why?
|
| Lymphoma | 1 | 2024 | 325 | 0.170 |
Why?
|
| DNA Damage | 7 | 2018 | 512 | 0.170 |
Why?
|
| RNA Stability | 2 | 2022 | 75 | 0.170 |
Why?
|
| Mitosis | 1 | 2021 | 186 | 0.170 |
Why?
|
| Hospitalization | 4 | 2024 | 1927 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 158 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 163 | 0.170 |
Why?
|
| Aldehyde-Lyases | 1 | 2020 | 5 | 0.160 |
Why?
|
| Cannabis | 1 | 2021 | 49 | 0.160 |
Why?
|
| Furin | 1 | 2020 | 6 | 0.160 |
Why?
|
| Varenicline | 1 | 2020 | 12 | 0.160 |
Why?
|
| GABAergic Neurons | 1 | 2021 | 66 | 0.160 |
Why?
|
| Transketolase | 1 | 2020 | 17 | 0.160 |
Why?
|
| Nicotinic Agonists | 1 | 2020 | 33 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2020 | 16 | 0.160 |
Why?
|
| NADP | 1 | 2020 | 52 | 0.160 |
Why?
|
| HLA-B Antigens | 3 | 2010 | 30 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 225 | 0.160 |
Why?
|
| Evolution, Molecular | 4 | 2014 | 655 | 0.160 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 39 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 85 | 0.160 |
Why?
|
| Cotinine | 3 | 2021 | 26 | 0.160 |
Why?
|
| Sex Characteristics | 7 | 2019 | 323 | 0.160 |
Why?
|
| Triglycerides | 4 | 2016 | 605 | 0.160 |
Why?
|
| Diabetic Retinopathy | 1 | 2021 | 85 | 0.160 |
Why?
|
| Cluster Analysis | 4 | 2024 | 417 | 0.160 |
Why?
|
| Heart Failure | 2 | 2024 | 2313 | 0.160 |
Why?
|
| Dermatomyositis | 3 | 2015 | 35 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 2 | 2022 | 449 | 0.160 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2023 | 103 | 0.160 |
Why?
|
| New Hampshire | 4 | 2026 | 7 | 0.160 |
Why?
|
| Open Reading Frames | 2 | 2014 | 198 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1065 | 0.160 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2022 | 175 | 0.160 |
Why?
|
| Sarcoma | 3 | 2012 | 216 | 0.160 |
Why?
|
| Autoimmunity | 2 | 2018 | 174 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 219 | 0.160 |
Why?
|
| Air Pollutants | 1 | 2021 | 124 | 0.150 |
Why?
|
| Histidine Ammonia-Lyase | 1 | 2019 | 4 | 0.150 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2019 | 29 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2023 | 270 | 0.150 |
Why?
|
| Pyrroline Carboxylate Reductases | 1 | 2019 | 6 | 0.150 |
Why?
|
| RNA Polymerase III | 1 | 2019 | 41 | 0.150 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 6 | 2007 | 10 | 0.150 |
Why?
|
| Cleft Lip | 3 | 2000 | 192 | 0.150 |
Why?
|
| Markov Chains | 3 | 2010 | 101 | 0.150 |
Why?
|
| Parents | 2 | 2020 | 1109 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2007 | 84 | 0.150 |
Why?
|
| Cleft Palate | 3 | 2000 | 219 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1275 | 0.150 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2021 | 149 | 0.150 |
Why?
|
| Deoxyribonuclease I | 1 | 2019 | 26 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2019 | 93 | 0.150 |
Why?
|
| Pharmacogenetics | 3 | 2021 | 203 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 419 | 0.150 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 85 | 0.150 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 196 | 0.150 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 661 | 0.150 |
Why?
|
| MutS Homolog 2 Protein | 7 | 2005 | 39 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 81 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2010 | 58 | 0.150 |
Why?
|
| Proteomics | 1 | 2023 | 607 | 0.150 |
Why?
|
| Molecular Sequence Data | 14 | 2015 | 3487 | 0.150 |
Why?
|
| Disease Progression | 11 | 2024 | 2203 | 0.150 |
Why?
|
| Monoamine Oxidase | 1 | 1999 | 18 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 252 | 0.150 |
Why?
|
| Receptors, Immunologic | 3 | 2018 | 124 | 0.150 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2026 | 41 | 0.150 |
Why?
|
| Disease Susceptibility | 12 | 2007 | 280 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2B6 | 2 | 2022 | 14 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 382 | 0.150 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2016 | 5 | 0.150 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2018 | 7 | 0.140 |
Why?
|
| Chemokines | 1 | 2019 | 123 | 0.140 |
Why?
|
| Receptors, Interleukin | 2 | 2009 | 36 | 0.140 |
Why?
|
| Mucins | 1 | 2019 | 69 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2007 | 783 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 420 | 0.140 |
Why?
|
| Survivors | 2 | 2021 | 345 | 0.140 |
Why?
|
| Chromosomes, Human, X | 2 | 2016 | 155 | 0.140 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 58 | 0.140 |
Why?
|
| Carcinogens, Environmental | 1 | 2018 | 12 | 0.140 |
Why?
|
| Epoxide Hydrolases | 3 | 2010 | 36 | 0.140 |
Why?
|
| RNA Splice Sites | 2 | 2015 | 92 | 0.140 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2016 | 19 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2012 | 48 | 0.140 |
Why?
|
| Abiraterone Acetate | 1 | 2018 | 1 | 0.140 |
Why?
|
| Cell Cycle | 4 | 2013 | 598 | 0.140 |
Why?
|
| Carcinoma, Medullary | 3 | 2014 | 17 | 0.140 |
Why?
|
| Insulin Resistance | 2 | 2021 | 683 | 0.140 |
Why?
|
| Lipids | 3 | 2017 | 562 | 0.140 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 363 | 0.140 |
Why?
|
| Intestinal Polyps | 3 | 2009 | 29 | 0.140 |
Why?
|
| Time Factors | 10 | 2021 | 6183 | 0.140 |
Why?
|
| Ultraviolet Rays | 3 | 2020 | 191 | 0.140 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 374 | 0.140 |
Why?
|
| Epigenesis, Genetic | 3 | 2023 | 768 | 0.140 |
Why?
|
| Vitiligo | 1 | 2018 | 10 | 0.140 |
Why?
|
| Thymus Gland | 2 | 1997 | 101 | 0.140 |
Why?
|
| Biomarkers | 7 | 2023 | 3395 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 543 | 0.140 |
Why?
|
| Italy | 3 | 2013 | 111 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 26 | 0.140 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2018 | 17 | 0.140 |
Why?
|
| Glutamine | 1 | 2019 | 204 | 0.140 |
Why?
|
| Cholesterol, LDL | 6 | 2021 | 615 | 0.140 |
Why?
|
| Founder Effect | 3 | 2009 | 32 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 225 | 0.140 |
Why?
|
| Mutagenicity Tests | 5 | 2007 | 20 | 0.140 |
Why?
|
| Matrix Metalloproteinase 16 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Tolloid-Like Metalloproteinases | 1 | 2017 | 2 | 0.130 |
Why?
|
| ADAMTS Proteins | 1 | 2017 | 10 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 91 | 0.130 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 187 | 0.130 |
Why?
|
| Arylalkylamine N-Acetyltransferase | 1 | 2017 | 1 | 0.130 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 10 | 0.130 |
Why?
|
| Peptides | 3 | 2018 | 708 | 0.130 |
Why?
|
| Mining | 2 | 2018 | 8 | 0.130 |
Why?
|
| Uranium | 2 | 2018 | 7 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 379 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 408 | 0.130 |
Why?
|
| Glycoproteins | 2 | 2017 | 346 | 0.130 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2017 | 64 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 11 | 2025 | 4698 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2021 | 492 | 0.130 |
Why?
|
| Caudate Nucleus | 1 | 2017 | 35 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2014 | 11 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 2 | 0.130 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Mice | 21 | 2025 | 18180 | 0.130 |
Why?
|
| Calcium Signaling | 1 | 2019 | 241 | 0.130 |
Why?
|
| International Cooperation | 2 | 2015 | 156 | 0.130 |
Why?
|
| Microscopic Polyangiitis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Myeloblastin | 1 | 2017 | 18 | 0.130 |
Why?
|
| Cytochrome P450 Family 4 | 1 | 2017 | 5 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 123 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 353 | 0.130 |
Why?
|
| Behavior, Addictive | 1 | 2017 | 56 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 216 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 48 | 0.130 |
Why?
|
| Virus Integration | 1 | 2017 | 37 | 0.130 |
Why?
|
| Child, Preschool | 18 | 2023 | 14982 | 0.130 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 60 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 134 | 0.130 |
Why?
|
| Cytokines | 2 | 2022 | 1331 | 0.130 |
Why?
|
| Phosphoproteins | 2 | 2019 | 432 | 0.130 |
Why?
|
| Infant | 16 | 2023 | 13276 | 0.130 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 81 | 0.130 |
Why?
|
| Cholesterol, HDL | 3 | 1990 | 394 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 428 | 0.130 |
Why?
|
| Exoribonucleases | 1 | 2016 | 21 | 0.130 |
Why?
|
| Cell Transformation, Viral | 1 | 2017 | 96 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 45 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 161 | 0.130 |
Why?
|
| Sirolimus | 2 | 2009 | 229 | 0.120 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2016 | 7 | 0.120 |
Why?
|
| Bacterial Vaccines | 1 | 1997 | 101 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2017 | 72 | 0.120 |
Why?
|
| Gelsolin | 1 | 2016 | 13 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 299 | 0.120 |
Why?
|
| HLA-D Antigens | 2 | 1999 | 8 | 0.120 |
Why?
|
| Transcription Factor TFIIH | 1 | 2016 | 6 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 1427 | 0.120 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2024 | 149 | 0.120 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2016 | 32 | 0.120 |
Why?
|
| Surgeons | 1 | 2021 | 286 | 0.120 |
Why?
|
| Benchmarking | 1 | 2017 | 135 | 0.120 |
Why?
|
| Integrins | 1 | 2016 | 90 | 0.120 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2017 | 126 | 0.120 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 54 | 0.120 |
Why?
|
| Exome | 3 | 2016 | 1075 | 0.120 |
Why?
|
| Organic Cation Transport Proteins | 3 | 2005 | 16 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 158 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1203 | 0.120 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2016 | 15 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli | 5 | 2007 | 45 | 0.120 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 59 | 0.120 |
Why?
|
| Myositis, Inclusion Body | 1 | 2017 | 57 | 0.120 |
Why?
|
| Nitrosamines | 2 | 2013 | 15 | 0.120 |
Why?
|
| Apolipoproteins B | 4 | 1996 | 144 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 463 | 0.120 |
Why?
|
| Wnt Proteins | 1 | 2017 | 193 | 0.120 |
Why?
|
| Genetic Carrier Screening | 5 | 2007 | 69 | 0.120 |
Why?
|
| Chickenpox | 1 | 2016 | 22 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2017 | 256 | 0.120 |
Why?
|
| DNA Repair Enzymes | 2 | 2016 | 37 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2019 | 316 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 112 | 0.120 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2014 | 36 | 0.120 |
Why?
|
| Nucleic Acid Conformation | 1 | 2016 | 180 | 0.120 |
Why?
|
| Endoribonucleases | 1 | 2016 | 85 | 0.120 |
Why?
|
| Cardiology | 1 | 2021 | 510 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 992 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2013 | 188 | 0.120 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 7 | 2006 | 65 | 0.120 |
Why?
|
| Kidney Neoplasms | 4 | 2008 | 419 | 0.120 |
Why?
|
| Health Promotion | 1 | 2019 | 407 | 0.120 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2015 | 20 | 0.110 |
Why?
|
| Mice, Inbred C3H | 7 | 2002 | 97 | 0.110 |
Why?
|
| Confidence Intervals | 5 | 2021 | 269 | 0.110 |
Why?
|
| Neuroglia | 1 | 2017 | 223 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2014 | 360 | 0.110 |
Why?
|
| Blood | 1 | 2015 | 99 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1788 | 0.110 |
Why?
|
| Pulmonary Fibrosis | 3 | 2002 | 114 | 0.110 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2015 | 32 | 0.110 |
Why?
|
| Glaucoma | 1 | 2016 | 87 | 0.110 |
Why?
|
| Twins, Monozygotic | 3 | 2012 | 124 | 0.110 |
Why?
|
| Gene Dosage | 3 | 2016 | 439 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 305 | 0.110 |
Why?
|
| Ataxin-2 | 1 | 2015 | 7 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 58 | 0.110 |
Why?
|
| Lipoproteins | 3 | 1993 | 182 | 0.110 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2016 | 152 | 0.110 |
Why?
|
| RNA | 2 | 2015 | 518 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 174 | 0.110 |
Why?
|
| Metabolome | 1 | 2017 | 323 | 0.110 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2014 | 3 | 0.110 |
Why?
|
| Adiposity | 1 | 2016 | 207 | 0.110 |
Why?
|
| 3' Untranslated Regions | 2 | 2021 | 155 | 0.110 |
Why?
|
| Qb-SNARE Proteins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 190 | 0.110 |
Why?
|
| Muscle Proteins | 2 | 2015 | 403 | 0.110 |
Why?
|
| beta Karyopherins | 1 | 2014 | 16 | 0.110 |
Why?
|
| Codon | 3 | 2010 | 93 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2010 | 238 | 0.110 |
Why?
|
| Antibodies, Bacterial | 1 | 1997 | 412 | 0.110 |
Why?
|
| Sjogren's Syndrome | 1 | 2016 | 108 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 20 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 394 | 0.110 |
Why?
|
| Sputum | 1 | 2015 | 115 | 0.110 |
Why?
|
| Chromatin | 2 | 2024 | 502 | 0.110 |
Why?
|
| Crossing Over, Genetic | 2 | 2011 | 53 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2024 | 1452 | 0.110 |
Why?
|
| Israel | 3 | 2024 | 48 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 48 | 0.110 |
Why?
|
| Glutathione Transferase | 3 | 2008 | 146 | 0.110 |
Why?
|
| Exercise | 1 | 2020 | 864 | 0.100 |
Why?
|
| SEER Program | 2 | 2018 | 212 | 0.100 |
Why?
|
| HLA-DQ Antigens | 2 | 2009 | 22 | 0.100 |
Why?
|
| Appendiceal Neoplasms | 1 | 2014 | 22 | 0.100 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 14 | 0.100 |
Why?
|
| Immunity, Innate | 2 | 2021 | 404 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2021 | 949 | 0.100 |
Why?
|
| Osteopontin | 1 | 2014 | 52 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 790 | 0.100 |
Why?
|
| Mexican Americans | 6 | 2002 | 162 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2015 | 310 | 0.100 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2010 | 63 | 0.100 |
Why?
|
| Area Under Curve | 5 | 2013 | 319 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2022 | 273 | 0.100 |
Why?
|
| Semaphorins | 1 | 2013 | 35 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 63 | 0.100 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 151 | 0.100 |
Why?
|
| Liver | 1 | 2021 | 1802 | 0.100 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Skin Pigmentation | 1 | 2013 | 28 | 0.100 |
Why?
|
| Homeostasis | 1 | 2017 | 715 | 0.100 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2013 | 48 | 0.100 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 188 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 84 | 0.100 |
Why?
|
| Infant, Newborn | 9 | 2024 | 8525 | 0.100 |
Why?
|
| Suntan | 1 | 2012 | 1 | 0.100 |
Why?
|
| Publications | 1 | 2013 | 36 | 0.100 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cytochrome P-450 CYP1A1 | 2 | 2010 | 82 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2003 | 211 | 0.100 |
Why?
|
| DNA Primers | 7 | 2015 | 604 | 0.100 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2012 | 25 | 0.100 |
Why?
|
| Seizures | 1 | 2018 | 876 | 0.090 |
Why?
|
| Cooperative Behavior | 2 | 2013 | 222 | 0.090 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 38 | 0.090 |
Why?
|
| Skin Diseases | 1 | 1994 | 141 | 0.090 |
Why?
|
| Sirtuin 1 | 1 | 2013 | 56 | 0.090 |
Why?
|
| Genealogy and Heraldry | 1 | 2012 | 9 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 850 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2024 | 184 | 0.090 |
Why?
|
| Citrulline | 1 | 2014 | 124 | 0.090 |
Why?
|
| Human Genome Project | 1 | 2012 | 55 | 0.090 |
Why?
|
| Particulate Matter | 2 | 2024 | 90 | 0.090 |
Why?
|
| Acetylesterase | 1 | 2012 | 1 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 271 | 0.090 |
Why?
|
| Internet | 4 | 2013 | 418 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 1211 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2012 | 25 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 186 | 0.090 |
Why?
|
| Microbiota | 1 | 2017 | 444 | 0.090 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2012 | 43 | 0.090 |
Why?
|
| Exodeoxyribonucleases | 1 | 2012 | 51 | 0.090 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2011 | 14 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2018 | 91 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 173 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2018 | 78 | 0.090 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2009 | 125 | 0.090 |
Why?
|
| Syndrome | 4 | 2009 | 1160 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 146 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1893 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 749 | 0.090 |
Why?
|
| Twins | 2 | 2006 | 70 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 3030 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 367 | 0.090 |
Why?
|
| Drug Approval | 1 | 2011 | 46 | 0.090 |
Why?
|
| Hypertension | 3 | 2015 | 1356 | 0.090 |
Why?
|
| Scopolamine Derivatives | 1 | 2011 | 11 | 0.090 |
Why?
|
| Blood Pressure | 4 | 2022 | 1337 | 0.090 |
Why?
|
| Medical Informatics | 3 | 2013 | 106 | 0.090 |
Why?
|
| CD30 Ligand | 1 | 2011 | 1 | 0.090 |
Why?
|
| CTLA-4 Antigen | 3 | 2023 | 64 | 0.090 |
Why?
|
| TNF Receptor-Associated Factor 1 | 2 | 2008 | 5 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Nevus, Pigmented | 1 | 2011 | 30 | 0.090 |
Why?
|
| Mice, Knockout | 5 | 2025 | 3812 | 0.080 |
Why?
|
| Genetic Heterogeneity | 5 | 2020 | 133 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2007 | 201 | 0.080 |
Why?
|
| Quinolones | 1 | 2011 | 55 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2014 | 1222 | 0.080 |
Why?
|
| Fatty Acid Desaturases | 2 | 2023 | 13 | 0.080 |
Why?
|
| Indans | 1 | 2011 | 52 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 101 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 2 | 2012 | 18 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 96 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 9 | 0.080 |
Why?
|
| Quality of Life | 5 | 2017 | 2070 | 0.080 |
Why?
|
| Risk Management | 1 | 2011 | 65 | 0.080 |
Why?
|
| Twins, Dizygotic | 3 | 2007 | 45 | 0.080 |
Why?
|
| Twin Studies as Topic | 1 | 2010 | 13 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2010 | 28 | 0.080 |
Why?
|
| Cyclin D1 | 2 | 2001 | 108 | 0.080 |
Why?
|
| Crosses, Genetic | 3 | 2007 | 151 | 0.080 |
Why?
|
| Behcet Syndrome | 1 | 2010 | 14 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 325 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2006 | 148 | 0.080 |
Why?
|
| Somatomedins | 2 | 2000 | 33 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 115 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3841 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2023 | 227 | 0.080 |
Why?
|
| Colon | 2 | 2026 | 355 | 0.080 |
Why?
|
| CD2 Antigens | 1 | 2009 | 8 | 0.080 |
Why?
|
| CD58 Antigens | 1 | 2009 | 7 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 93 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2021 | 12852 | 0.080 |
Why?
|
| Mathematics | 4 | 2004 | 71 | 0.080 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 154 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2024 | 60 | 0.080 |
Why?
|
| Loss of Heterozygosity | 2 | 2007 | 124 | 0.080 |
Why?
|
| Folic Acid | 2 | 2020 | 271 | 0.080 |
Why?
|
| Insulin | 2 | 2017 | 1146 | 0.080 |
Why?
|
| Interleukin-12 Receptor beta 2 Subunit | 1 | 2009 | 1 | 0.080 |
Why?
|
| CD28 Antigens | 1 | 2009 | 76 | 0.080 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Thrombopoietin | 1 | 2009 | 30 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2022 | 669 | 0.080 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 100 | 0.080 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2009 | 34 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 32 | 0.070 |
Why?
|
| Genetics, Medical | 2 | 2001 | 120 | 0.070 |
Why?
|
| Thrombocytosis | 1 | 2009 | 34 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2010 | 186 | 0.070 |
Why?
|
| RGS Proteins | 1 | 2009 | 47 | 0.070 |
Why?
|
| Familial Mediterranean Fever | 2 | 1999 | 4 | 0.070 |
Why?
|
| Glucose | 2 | 2025 | 853 | 0.070 |
Why?
|
| Genes, Recessive | 4 | 2004 | 199 | 0.070 |
Why?
|
| DNA Replication | 1 | 2011 | 357 | 0.070 |
Why?
|
| CD40 Antigens | 1 | 2008 | 25 | 0.070 |
Why?
|
| Genes, Overlapping | 1 | 2008 | 7 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2008 | 37 | 0.070 |
Why?
|
| Chi-Square Distribution | 5 | 2010 | 561 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 221 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2011 | 157 | 0.070 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 78 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 70 | 0.070 |
Why?
|
| Self Report | 2 | 2022 | 556 | 0.070 |
Why?
|
| Amino Acid Substitution | 3 | 2004 | 407 | 0.070 |
Why?
|
| Jejunum | 2 | 2001 | 122 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 508 | 0.070 |
Why?
|
| Hepatitis C Antigens | 1 | 2008 | 2 | 0.070 |
Why?
|
| Wnt Signaling Pathway | 2 | 2022 | 207 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 680 | 0.070 |
Why?
|
| Receptors, KIR | 1 | 2008 | 10 | 0.070 |
Why?
|
| Heterosexuality | 1 | 2008 | 8 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2001 | 640 | 0.070 |
Why?
|
| Matched-Pair Analysis | 3 | 2003 | 28 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 57 | 0.070 |
Why?
|
| Schizophrenia | 1 | 1991 | 326 | 0.070 |
Why?
|
| Genes, ras | 2 | 2005 | 98 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2006 | 323 | 0.070 |
Why?
|
| Contraception Behavior | 1 | 2008 | 28 | 0.070 |
Why?
|
| Hamartoma | 2 | 2005 | 51 | 0.070 |
Why?
|
| Base Pair Mismatch | 3 | 2006 | 19 | 0.070 |
Why?
|
| Chromosome Segregation | 2 | 2005 | 68 | 0.070 |
Why?
|
| Chromatids | 2 | 2005 | 32 | 0.070 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 160 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 92 | 0.070 |
Why?
|
| Complement C5 | 1 | 2007 | 6 | 0.070 |
Why?
|
| STAT4 Transcription Factor | 1 | 2007 | 11 | 0.070 |
Why?
|
| Wilms Tumor | 2 | 2000 | 117 | 0.070 |
Why?
|
| Fatty Acids | 2 | 2023 | 377 | 0.070 |
Why?
|
| Gene Ontology | 2 | 2018 | 52 | 0.070 |
Why?
|
| Consensus | 2 | 2023 | 529 | 0.070 |
Why?
|
| Complement Factor H | 1 | 2007 | 24 | 0.070 |
Why?
|
| Maine | 2 | 2019 | 11 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2007 | 9 | 0.070 |
Why?
|
| DNA Breaks | 1 | 2007 | 25 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 5 | 2010 | 59 | 0.060 |
Why?
|
| Recurrence | 2 | 2021 | 1475 | 0.060 |
Why?
|
| Safe Sex | 1 | 2007 | 14 | 0.060 |
Why?
|
| Asthma | 3 | 2026 | 909 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.060 |
Why?
|
| Time | 1 | 2007 | 93 | 0.060 |
Why?
|
| Apolipoproteins A | 1 | 1987 | 52 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 232 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2008 | 200 | 0.060 |
Why?
|
| Interdisciplinary Communication | 2 | 2020 | 132 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 33 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 398 | 0.060 |
Why?
|
| Social Responsibility | 1 | 2007 | 84 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2012 | 107 | 0.060 |
Why?
|
| DNA Helicases | 2 | 2014 | 233 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2008 | 203 | 0.060 |
Why?
|
| fas Receptor | 1 | 2006 | 40 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 137 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2006 | 32 | 0.060 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2026 | 5 | 0.060 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 71 | 0.060 |
Why?
|
| HLA-DR4 Antigen | 2 | 1996 | 6 | 0.060 |
Why?
|
| Australia | 3 | 2014 | 174 | 0.060 |
Why?
|
| Macular Degeneration | 1 | 2007 | 90 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 135 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 209 | 0.060 |
Why?
|
| Mass Screening | 3 | 2021 | 807 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 316 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 235 | 0.060 |
Why?
|
| Japan | 3 | 2014 | 166 | 0.060 |
Why?
|
| Carnitine | 2 | 2022 | 70 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 1997 | 227 | 0.060 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2025 | 15 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2008 | 480 | 0.060 |
Why?
|
| Molecular Sequence Annotation | 2 | 2017 | 150 | 0.060 |
Why?
|
| China | 2 | 2019 | 281 | 0.060 |
Why?
|
| Forced Expiratory Volume | 2 | 2020 | 177 | 0.060 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 48 | 0.060 |
Why?
|
| Internationality | 2 | 2018 | 128 | 0.060 |
Why?
|
| Truth Disclosure | 2 | 2013 | 109 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 427 | 0.060 |
Why?
|
| Attitude to Health | 3 | 2007 | 244 | 0.060 |
Why?
|
| Income | 3 | 2015 | 137 | 0.050 |
Why?
|
| Adipose Tissue, White | 1 | 2025 | 96 | 0.050 |
Why?
|
| Rural Population | 2 | 2019 | 264 | 0.050 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2024 | 5 | 0.050 |
Why?
|
| Sex Distribution | 3 | 2016 | 315 | 0.050 |
Why?
|
| A549 Cells | 1 | 2024 | 48 | 0.050 |
Why?
|
| Genes, myc | 1 | 2024 | 94 | 0.050 |
Why?
|
| Structural Homology, Protein | 1 | 2004 | 27 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2025 | 113 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 96 | 0.050 |
Why?
|
| MutL Proteins | 2 | 2001 | 14 | 0.050 |
Why?
|
| Asia | 2 | 2017 | 125 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 322 | 0.050 |
Why?
|
| Carotenoids | 1 | 2005 | 77 | 0.050 |
Why?
|
| Sister Chromatid Exchange | 2 | 2007 | 15 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2024 | 53 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 115 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 658 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2110 | 0.050 |
Why?
|
| Research Personnel | 1 | 2025 | 142 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 2 | 2016 | 6 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 366 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2016 | 394 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 166 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2024 | 139 | 0.050 |
Why?
|
| Whole Body Imaging | 1 | 2023 | 29 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 96 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1380 | 0.050 |
Why?
|
| Polycythemia | 1 | 2003 | 45 | 0.050 |
Why?
|
| Mitoguazone | 1 | 2022 | 3 | 0.050 |
Why?
|
| Diseases in Twins | 2 | 1995 | 88 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2023 | 38 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2023 | 50 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 58 | 0.050 |
Why?
|
| RNA Splicing Factors | 1 | 2023 | 51 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 752 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2023 | 80 | 0.050 |
Why?
|
| Diet | 3 | 2013 | 1116 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2008 | 1605 | 0.050 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2022 | 10 | 0.050 |
Why?
|
| Community Networks | 1 | 2022 | 30 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2020 | 1625 | 0.050 |
Why?
|
| TYK2 Kinase | 1 | 2022 | 4 | 0.050 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2002 | 22 | 0.050 |
Why?
|
| Death Certificates | 1 | 2002 | 10 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2020 | 893 | 0.050 |
Why?
|
| Nod2 Signaling Adaptor Protein | 3 | 2010 | 21 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 335 | 0.050 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2022 | 4 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2024 | 301 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2000 | 266 | 0.050 |
Why?
|
| Tumor Protein p73 | 3 | 2008 | 26 | 0.050 |
Why?
|
| Universities | 1 | 2022 | 123 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 528 | 0.050 |
Why?
|
| Nucleotides | 1 | 2022 | 89 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2009 | 170 | 0.050 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 19 | 0.040 |
Why?
|
| Cholesterol | 4 | 1996 | 541 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2025 | 451 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2022 | 107 | 0.040 |
Why?
|
| Taxoids | 2 | 2016 | 72 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 325 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2022 | 77 | 0.040 |
Why?
|
| Measles Vaccine | 1 | 2001 | 12 | 0.040 |
Why?
|
| Indians, South American | 1 | 2001 | 10 | 0.040 |
Why?
|
| Nitrogen Dioxide | 1 | 2021 | 25 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2898 | 0.040 |
Why?
|
| Focus Groups | 1 | 2022 | 233 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 150 | 0.040 |
Why?
|
| Glycine | 1 | 2022 | 159 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 47 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 192 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2020 | 832 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2021 | 61 | 0.040 |
Why?
|
| Human Experimentation | 1 | 2001 | 33 | 0.040 |
Why?
|
| Proteome | 1 | 2023 | 289 | 0.040 |
Why?
|
| Decision Trees | 1 | 2001 | 57 | 0.040 |
Why?
|
| Photoperiod | 1 | 2021 | 19 | 0.040 |
Why?
|
| Measles | 1 | 2001 | 40 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 38 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2022 | 280 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 63 | 0.040 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2021 | 17 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2021 | 86 | 0.040 |
Why?
|
| Androgens | 1 | 2023 | 267 | 0.040 |
Why?
|
| Lipoprotein Lipase | 2 | 1998 | 61 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2022 | 114 | 0.040 |
Why?
|
| Multifactor Dimensionality Reduction | 1 | 2020 | 2 | 0.040 |
Why?
|
| Genes, Wilms Tumor | 1 | 2000 | 4 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2023 | 359 | 0.040 |
Why?
|
| Documentation | 1 | 2002 | 117 | 0.040 |
Why?
|
| Cell Line | 3 | 2013 | 2568 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2022 | 212 | 0.040 |
Why?
|
| Astronomy | 1 | 2020 | 1 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2021 | 148 | 0.040 |
Why?
|
| Minisatellite Repeats | 2 | 2002 | 43 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2020 | 695 | 0.040 |
Why?
|
| United States National Aeronautics and Space Administration | 1 | 2020 | 15 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 140 | 0.040 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2014 | 11 | 0.040 |
Why?
|
| Isothiocyanates | 1 | 2000 | 12 | 0.040 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.040 |
Why?
|
| Missouri | 1 | 2020 | 41 | 0.040 |
Why?
|
| Acetylation | 1 | 2001 | 182 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1999 | 57 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2015 | 32 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2014 | 40 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 65 | 0.040 |
Why?
|
| Histocompatibility Testing | 2 | 1999 | 107 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 154 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2021 | 140 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 149 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 414 | 0.040 |
Why?
|
| Depression | 3 | 1998 | 1316 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2002 | 225 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 576 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2019 | 9 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 718 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 43 | 0.040 |
Why?
|
| HIV Infections | 2 | 2007 | 2011 | 0.040 |
Why?
|
| Circadian Clocks | 1 | 2021 | 86 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 219 | 0.040 |
Why?
|
| HIV-1 | 2 | 1995 | 480 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 1999 | 20 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2020 | 90 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 82 | 0.040 |
Why?
|
| Platinum Compounds | 2 | 2011 | 5 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 306 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 171 | 0.040 |
Why?
|
| GPI-Linked Proteins | 2 | 2010 | 105 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 216 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2011 | 341 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 87 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 428 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 2 | 2009 | 55 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 223 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 72 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2019 | 117 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 157 | 0.040 |
Why?
|
| Automation | 1 | 1999 | 65 | 0.040 |
Why?
|
| Sunlight | 2 | 2012 | 26 | 0.040 |
Why?
|
| Zinc Fingers | 2 | 2014 | 117 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 25 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2021 | 323 | 0.040 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1998 | 9 | 0.040 |
Why?
|
| Platelet Count | 1 | 2019 | 138 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 508 | 0.040 |
Why?
|
| Clubfoot | 1 | 1998 | 21 | 0.040 |
Why?
|
| Autophagy | 1 | 2022 | 421 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 1995 | 489 | 0.040 |
Why?
|
| Unified Medical Language System | 1 | 2018 | 2 | 0.040 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 19 | 0.040 |
Why?
|
| Turkey | 2 | 2010 | 67 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 191 | 0.030 |
Why?
|
| Chromosomes | 1 | 1998 | 119 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 1998 | 7 | 0.030 |
Why?
|
| Social Identification | 1 | 1998 | 22 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1998 | 38 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 1998 | 43 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 463 | 0.030 |
Why?
|
| Antiporters | 1 | 1998 | 35 | 0.030 |
Why?
|
| Entropy | 2 | 2011 | 28 | 0.030 |
Why?
|
| Pseudogenes | 1 | 1998 | 50 | 0.030 |
Why?
|
| HLA-B40 Antigen | 1 | 1997 | 1 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2021 | 456 | 0.030 |
Why?
|
| Thyroid Neoplasms | 2 | 2012 | 249 | 0.030 |
Why?
|
| Myopia | 1 | 2018 | 120 | 0.030 |
Why?
|
| Puberty | 1 | 1998 | 93 | 0.030 |
Why?
|
| Neurofibromatosis 1 | 2 | 2005 | 71 | 0.030 |
Why?
|
| Inventions | 1 | 2017 | 19 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1998 | 64 | 0.030 |
Why?
|
| Chromosome Breakage | 1 | 1998 | 156 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2018 | 169 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 877 | 0.030 |
Why?
|
| Social Environment | 1 | 1998 | 114 | 0.030 |
Why?
|
| Iowa | 2 | 2002 | 13 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1250 | 0.030 |
Why?
|
| Apolipoproteins | 3 | 1994 | 69 | 0.030 |
Why?
|
| Educational Status | 2 | 2006 | 276 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 980 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 1998 | 106 | 0.030 |
Why?
|
| HLA-DP Antigens | 1 | 2017 | 5 | 0.030 |
Why?
|
| Aurora Kinases | 2 | 2007 | 26 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 62 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 56 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 15 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2017 | 29 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 131 | 0.030 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1997 | 6 | 0.030 |
Why?
|
| Netherlands | 2 | 2008 | 54 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 693 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1997 | 46 | 0.030 |
Why?
|
| Research Report | 1 | 2017 | 71 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 1997 | 73 | 0.030 |
Why?
|
| Peroxidase | 1 | 2017 | 63 | 0.030 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2017 | 26 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2016 | 24 | 0.030 |
Why?
|
| Centromere | 2 | 2012 | 69 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1163 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2013 | 1014 | 0.030 |
Why?
|
| Apolipoprotein C-II | 1 | 1996 | 4 | 0.030 |
Why?
|
| Lymphotoxin-alpha | 1 | 1996 | 7 | 0.030 |
Why?
|
| Apolipoproteins C | 1 | 1996 | 11 | 0.030 |
Why?
|
| Informed Consent | 1 | 1999 | 345 | 0.030 |
Why?
|
| Reward | 1 | 2017 | 113 | 0.030 |
Why?
|
| Motivation | 1 | 1999 | 327 | 0.030 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2016 | 4 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2016 | 23 | 0.030 |
Why?
|
| Louisiana | 4 | 1994 | 137 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 1231 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2021 | 1103 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 56 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2009 | 700 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 2397 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2011 | 690 | 0.030 |
Why?
|
| Cerebellar Ataxia | 1 | 1997 | 62 | 0.030 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 37 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1997 | 227 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2016 | 59 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1997 | 146 | 0.030 |
Why?
|
| Clinical Laboratory Services | 1 | 2016 | 19 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2016 | 14 | 0.030 |
Why?
|
| Birth Order | 2 | 1995 | 8 | 0.030 |
Why?
|
| Mouth | 1 | 2016 | 65 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2001 | 765 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 207 | 0.030 |
Why?
|
| Fasting | 1 | 2017 | 304 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 2016 | 52 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 112 | 0.030 |
Why?
|
| HLA-DR Serological Subtypes | 1 | 1995 | 1 | 0.030 |
Why?
|
| HLA-DRB3 Chains | 1 | 1995 | 2 | 0.030 |
Why?
|
| Immunophilins | 1 | 2015 | 10 | 0.030 |
Why?
|
| Laboratories | 1 | 2016 | 79 | 0.030 |
Why?
|
| In Vitro Techniques | 3 | 2005 | 809 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 1997 | 174 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1166 | 0.030 |
Why?
|
| Proline | 1 | 1995 | 75 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2005 | 7 | 0.030 |
Why?
|
| Chorioretinitis | 1 | 1994 | 3 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 645 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 335 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2015 | 37 | 0.030 |
Why?
|
| Alopecia | 1 | 1995 | 41 | 0.030 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2015 | 68 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 26 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2016 | 155 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 307 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 358 | 0.030 |
Why?
|
| Solute Carrier Family 22 Member 5 | 2 | 2005 | 5 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 1143 | 0.030 |
Why?
|
| Reproductive History | 1 | 2014 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2015 | 97 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 350 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Calcium Carbonate | 1 | 2014 | 11 | 0.030 |
Why?
|
| Sampling Studies | 2 | 1998 | 75 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 222 | 0.030 |
Why?
|
| Arabidopsis | 1 | 2015 | 90 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 358 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 342 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 55 | 0.030 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mucocele | 1 | 2014 | 6 | 0.030 |
Why?
|
| Early Diagnosis | 2 | 2007 | 189 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2009 | 1569 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 24 | 0.030 |
Why?
|
| Egypt | 2 | 2005 | 29 | 0.030 |
Why?
|
| Uruguay | 1 | 2013 | 14 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1292 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2014 | 70 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 247 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 301 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 478 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 510 | 0.030 |
Why?
|
| Social Support | 3 | 2005 | 364 | 0.020 |
Why?
|
| Activation, Metabolic | 1 | 2013 | 4 | 0.020 |
Why?
|
| Eye Color | 1 | 2013 | 5 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 451 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 58 | 0.020 |
Why?
|
| Anxiety | 2 | 1997 | 1001 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2016 | 221 | 0.020 |
Why?
|
| Histones | 1 | 2017 | 544 | 0.020 |
Why?
|
| Employment | 1 | 2013 | 72 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2013 | 6 | 0.020 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 20 | 0.020 |
Why?
|
| Lymphangiogenesis | 1 | 2013 | 15 | 0.020 |
Why?
|
| MafF Transcription Factor | 1 | 2013 | 1 | 0.020 |
Why?
|
| Colorado | 1 | 2013 | 20 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 125 | 0.020 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 15 | 0.020 |
Why?
|
| Meat | 1 | 2013 | 44 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2013 | 15 | 0.020 |
Why?
|
| Denmark | 1 | 2013 | 28 | 0.020 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 122 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2013 | 24 | 0.020 |
Why?
|
| Melanins | 1 | 2012 | 17 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2015 | 728 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2012 | 18 | 0.020 |
Why?
|
| Sweden | 1 | 2013 | 56 | 0.020 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2012 | 21 | 0.020 |
Why?
|
| alpha-MSH | 1 | 2012 | 17 | 0.020 |
Why?
|
| District of Columbia | 1 | 1992 | 16 | 0.020 |
Why?
|
| Melanocytes | 1 | 2012 | 45 | 0.020 |
Why?
|
| Monophenol Monooxygenase | 1 | 2012 | 23 | 0.020 |
Why?
|
| Endonucleases | 1 | 2013 | 51 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 104 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 67 | 0.020 |
Why?
|
| Parity | 1 | 1993 | 82 | 0.020 |
Why?
|
| Neural Tube Defects | 1 | 2016 | 343 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1995 | 253 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 44 | 0.020 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 1992 | 4 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 220 | 0.020 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 19 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 73 | 0.020 |
Why?
|
| Keratins | 1 | 1992 | 49 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 161 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1993 | 105 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 165 | 0.020 |
Why?
|
| Pregnancy | 3 | 2021 | 7423 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2012 | 33 | 0.020 |
Why?
|
| GATA3 Transcription Factor | 1 | 2012 | 45 | 0.020 |
Why?
|
| Adolescent Development | 1 | 2012 | 29 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2012 | 10 | 0.020 |
Why?
|
| Enzyme Assays | 1 | 2012 | 11 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2012 | 27 | 0.020 |
Why?
|
| Analgesics | 1 | 2013 | 119 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2013 | 197 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2011 | 11 | 0.020 |
Why?
|
| Epithelium | 1 | 1993 | 337 | 0.020 |
Why?
|
| Utah | 1 | 1992 | 83 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Pancreas | 1 | 2013 | 222 | 0.020 |
Why?
|
| Health Personnel | 1 | 2017 | 548 | 0.020 |
Why?
|
| Apolipoprotein A-I | 2 | 1994 | 80 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 228 | 0.020 |
Why?
|
| Africa, Western | 1 | 2011 | 15 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 20 | 0.020 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1991 | 15 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2011 | 4 | 0.020 |
Why?
|
| Fruit | 1 | 2013 | 233 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| Tiotropium Bromide | 1 | 2011 | 14 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 33 | 0.020 |
Why?
|
| San Francisco | 1 | 1991 | 19 | 0.020 |
Why?
|
| Cephalometry | 1 | 1991 | 46 | 0.020 |
Why?
|
| Bronchi | 1 | 2011 | 99 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 34 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2011 | 35 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 415 | 0.020 |
Why?
|
| Spirometry | 1 | 2011 | 93 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2000 | 1610 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 192 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2019 | 890 | 0.020 |
Why?
|
| Ki-1 Antigen | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2011 | 46 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 348 | 0.020 |
Why?
|
| Smad4 Protein | 2 | 2002 | 58 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Singapore | 1 | 2010 | 16 | 0.020 |
Why?
|
| Qa-SNARE Proteins | 1 | 2010 | 21 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2010 | 13 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1993 | 317 | 0.020 |
Why?
|
| Korea | 1 | 2010 | 32 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 230 | 0.020 |
Why?
|
| Middle East | 1 | 2010 | 36 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 240 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1993 | 234 | 0.020 |
Why?
|
| Ikaros Transcription Factor | 1 | 2010 | 35 | 0.020 |
Why?
|
| Hair Follicle | 1 | 2010 | 31 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 217 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 165 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 51 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2000 | 40 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2000 | 42 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 214 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 70 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 814 | 0.020 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 1990 | 30 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 278 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 499 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2004 | 620 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 148 | 0.020 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 63 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2015 | 849 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 67 | 0.020 |
Why?
|
| Immune System | 1 | 2010 | 98 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 728 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 653 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2009 | 13 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
| Patient Selection | 2 | 2007 | 719 | 0.020 |
Why?
|
| Type A Personality | 1 | 1989 | 3 | 0.020 |
Why?
|
| Autophagy-Related Proteins | 1 | 2009 | 37 | 0.020 |
Why?
|
| Radiation, Ionizing | 2 | 2001 | 38 | 0.020 |
Why?
|
| Pulmonary Emphysema | 1 | 2010 | 95 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 172 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 25 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1989 | 39 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2005 | 68 | 0.020 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 1989 | 24 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 968 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 290 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 72 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2008 | 25 | 0.020 |
Why?
|
| DNA, Intergenic | 1 | 2008 | 18 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 256 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 81 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 233 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2009 | 178 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1996 | 876 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 380 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2467 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 105 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 653 | 0.020 |
Why?
|
| Economics, Medical | 1 | 2007 | 7 | 0.020 |
Why?
|
| Viremia | 1 | 2008 | 131 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 59 | 0.020 |
Why?
|
| Genetic Drift | 1 | 2007 | 20 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2007 | 50 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2006 | 9 | 0.020 |
Why?
|
| Tanzania | 1 | 2007 | 67 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 247 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 271 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2007 | 57 | 0.020 |
Why?
|
| Mastectomy | 1 | 2006 | 75 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2008 | 569 | 0.020 |
Why?
|
| Abnormalities, Multiple | 2 | 2005 | 970 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2006 | 6 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 19 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2007 | 81 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2007 | 94 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 156 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2006 | 36 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 424 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2006 | 17 | 0.020 |
Why?
|
| Genes, bcl-1 | 1 | 2006 | 4 | 0.020 |
Why?
|
| Dust | 1 | 2006 | 31 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 40 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 4 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 238 | 0.010 |
Why?
|
| Belgium | 1 | 2006 | 43 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 836 | 0.010 |
Why?
|
| Jordan | 1 | 2005 | 9 | 0.010 |
Why?
|
| Information Services | 1 | 2006 | 23 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2005 | 11 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 132 | 0.010 |
Why?
|
| Species Specificity | 2 | 1996 | 486 | 0.010 |
Why?
|
| Cytosine | 1 | 2006 | 57 | 0.010 |
Why?
|
| Joints | 1 | 2005 | 27 | 0.010 |
Why?
|
| Critical Pathways | 1 | 2006 | 76 | 0.010 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 57 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 341 | 0.010 |
Why?
|
| Maternal Age | 1 | 2006 | 133 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 64 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2006 | 71 | 0.010 |
Why?
|
| Cryptoxanthins | 1 | 2005 | 1 | 0.010 |
Why?
|
| Xanthophylls | 1 | 2005 | 3 | 0.010 |
Why?
|
| Selection Bias | 1 | 2005 | 17 | 0.010 |
Why?
|
| Zeaxanthins | 1 | 2005 | 8 | 0.010 |
Why?
|
| Suicide | 1 | 2008 | 198 | 0.010 |
Why?
|
| Isomerism | 1 | 2005 | 23 | 0.010 |
Why?
|
| Lutein | 1 | 2005 | 14 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1233 | 0.010 |
Why?
|
| Adenine | 1 | 2006 | 120 | 0.010 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2005 | 24 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 972 | 0.010 |
Why?
|
| Adaptation, Psychological | 2 | 1999 | 429 | 0.010 |
Why?
|
| beta Carotene | 1 | 2005 | 35 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 629 | 0.010 |
Why?
|
| RNA Probes | 1 | 2004 | 26 | 0.010 |
Why?
|
| Rheumatoid Nodule | 1 | 2004 | 2 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 52 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 2004 | 72 | 0.010 |
Why?
|
| Arthrography | 1 | 2004 | 6 | 0.010 |
Why?
|
| Organic Anion Transporters | 1 | 2004 | 23 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 324 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 74 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 34 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2004 | 125 | 0.010 |
Why?
|
| Social Class | 1 | 2005 | 206 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 202 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1994 | 131 | 0.010 |
Why?
|
| Chromosome Painting | 1 | 2002 | 15 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 42 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2002 | 17 | 0.010 |
Why?
|
| Finland | 1 | 2002 | 46 | 0.010 |
Why?
|
| Mississippi | 1 | 2002 | 35 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2002 | 35 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 242 | 0.010 |
Why?
|
| Reference Values | 2 | 1995 | 679 | 0.010 |
Why?
|
| Radiation Genetics | 1 | 2001 | 2 | 0.010 |
Why?
|
| Literature | 1 | 2001 | 4 | 0.010 |
Why?
|
| Venezuela | 1 | 2001 | 14 | 0.010 |
Why?
|
| Eugenics | 1 | 2001 | 3 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2005 | 495 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 62 | 0.010 |
Why?
|
| Schistosomiasis | 1 | 2001 | 52 | 0.010 |
Why?
|
| Methylation | 1 | 2001 | 197 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 3374 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 83 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 769 | 0.010 |
Why?
|
| England | 1 | 2001 | 59 | 0.010 |
Why?
|
| Delivery, Obstetric | 2 | 1995 | 255 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2000 | 32 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 2000 | 23 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 92 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 263 | 0.010 |
Why?
|
| Benzopyrenes | 1 | 2000 | 4 | 0.010 |
Why?
|
| Bioethics | 1 | 2001 | 80 | 0.010 |
Why?
|
| Smad7 Protein | 1 | 1999 | 5 | 0.010 |
Why?
|
| Statistical Distributions | 1 | 1999 | 3 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 451 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1999 | 54 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 1999 | 53 | 0.010 |
Why?
|
| beta Catenin | 1 | 2000 | 199 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 2000 | 129 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1999 | 33 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 1998 | 18 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 950 | 0.010 |
Why?
|
| Pyrin | 1 | 1998 | 2 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 1998 | 20 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 1998 | 24 | 0.010 |
Why?
|
| Renin | 1 | 1998 | 75 | 0.010 |
Why?
|
| Chloride-Bicarbonate Antiporters | 1 | 1998 | 8 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1998 | 49 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4654 | 0.010 |
Why?
|
| Minnesota | 1 | 1998 | 180 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 246 | 0.010 |
Why?
|
| Systole | 1 | 1998 | 193 | 0.010 |
Why?
|
| Diastole | 1 | 1998 | 178 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1998 | 39 | 0.010 |
Why?
|
| Spouses | 1 | 1997 | 70 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2001 | 791 | 0.010 |
Why?
|
| Calcium Channels, N-Type | 1 | 1997 | 46 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2000 | 323 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1996 | 85 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1997 | 83 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 986 | 0.010 |
Why?
|
| Rabbits | 1 | 1997 | 573 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1998 | 400 | 0.010 |
Why?
|
| Testosterone | 1 | 2001 | 590 | 0.010 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1994 | 16 | 0.010 |
Why?
|
| Mexico | 1 | 1995 | 188 | 0.010 |
Why?
|
| Site-Specific DNA-Methyltransferase (Adenine-Specific) | 1 | 1994 | 11 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1994 | 47 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 501 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 168 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1917 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 1994 | 39 | 0.010 |
Why?
|
| Decision Making | 1 | 1999 | 687 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 333 | 0.010 |
Why?
|
| Minority Groups | 1 | 1995 | 257 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1992 | 15 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 122 | 0.010 |
Why?
|
| Triplets | 1 | 1991 | 9 | 0.010 |
Why?
|
| Birth Weight | 1 | 1991 | 342 | 0.000 |
Why?
|
| Personality Tests | 1 | 1989 | 17 | 0.000 |
Why?
|
| Neuroma | 1 | 1989 | 4 | 0.000 |
Why?
|
| Personality Development | 1 | 1989 | 15 | 0.000 |
Why?
|
| Pheochromocytoma | 1 | 1989 | 32 | 0.000 |
Why?
|
| Cesarean Section | 1 | 1991 | 426 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1989 | 67 | 0.000 |
Why?
|
| Acid Phosphatase | 1 | 1987 | 13 | 0.000 |
Why?
|
| Global Health | 1 | 1991 | 626 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1987 | 61 | 0.000 |
Why?
|